Malignant hyperthermia mutations and correlation with the severity of the anesthetic complication and the level of the in vitro contracture tests Background: Malignant hyperthermia (MH) is a complication of anaesthesia appearing as an acute potentially lethal hypermetabolic state in people carrying a genetic anomaly expressed in the skeletal muscle. MH susceptibility can be diagnosed by in vitro contracture test (IVCT) with halothane and caffeine requiring muscular biopsy, or by looking for the MH mutations directly in DNA extracted from the blood. Studies showed an influence of the type of mutation (genotype) on the various expressions (phenotypes) of the MH susceptibility. The aims of this study are to look for any correlation between the presence of a MH mutation and 1) the severity of the anesthetic complication and 2) the force of the contractures observed in the IVCT. Materials and methods: Observational analytical retrospective anonymized study based on the informations contained in the Lille MH Database. The criteria of inclusion were: 1) anesthetic probands classified as MHS according to the IVCT and/or the presence of a MH mutation in the RYR1 gene in at least one family member and 2) existence of sufficient clinical information concerning the crisis. The severity of the MH crisis was classified as: death, survival after stay in intensive care unit ICU, survival without stay in ICU. The results of the IVCT: maximal force of contracture at halothane 2%, caffeine 2mmol/L, halothane 3%. The statistical analysis was carried out with a test of Chi-2 for the comparisons of frequency and a test of Mann Whitney for the nonparametric variables with p<0,05 significant. Results: 92 MHS probands were included in the study: 63 men (68%) and 29 women (32%) over a period going from 1964 to 2013. The age at the moment of the crisis is 18,9 years (DS 13,3). Mutations were found in 59 families (64%) including 53 causal mutations (58%) and 6 probable (6%). No significant difference was observed in the degree of severity between the 2 populations. The force of contracture of the IVCT was significantly higher in the group with MH (Table 1) . Conclusions: In this study, the severity of the MH crisis is not related to the presence of MH mutations. It is well known that the severity is more dependent on environmental factors, age of the crisis, exposure time to the volatile anesthetic agents, administration of dantrolene. On the other hand, the presence of a MH mutation in gene RYR1 modifies the muscular phenotype since the force of contracture in the IVCT is significantly more important in this group. These results support the genetic heterogeneity of the disease.
Although negative patients may be happy to result negative, they remain worried regarding anaesthesia own and of their relatives. The worry for General Anesthesia (GA) does not disappear with a negative test and it may be very difficult explaining that other possible causes may be involved in MH like reactions. In some MHN probands it may be easier to find an explanation, as it is possible an alternative diagnosis or because…. the not clear or wrong anaesthetic report but what about the others. In some of similar cases, we decide to perform a genetic analysis and in one patient MHN patient we found a "no causative mutation". At this point the question is 1) can be assure the MHN patients regarding GA with trigger agents? 2) Are there other possible investigations to give more assurance to such patients? 3) genetic testing should be prescribed also in the MHN probands? We present the data of our MH laboratories highlighting the IVCT and genetic results obtained on our probands and the suggestions and information that we give to the MHN probands as well as some questions to the auditorium. Background: The provision of a Quality Assurance Scheme for members of the European Malignant Hyperthermia Group (EMHG) is to ensure that the concentrations of halothane and caffeine in the tissue bath are as stipulated in the in vitro contracture test (IVCT) protocol. Confirmation of the correct concentrations in the tissue bath is an essential part of the IVCT protocol. The focus of this presentation will be to provide an update of the QA results from the analysis of both halothane and caffeine from all of the participating units over a period of three years. The aims are to show 1. How many malignant hyperthermia (MH) units have achieved the target concentrations of halothane for nominal vaporiser settings of 0.5% (0.11mM) and 2.0% (0.44mM) and caffeine concentrations of 0.5mM and 2.0mM? 2. How these halothane concentrations can vary within each lab? Results: Each lab is aware of its own results. Anonymised results from January 2012 to January 2014 will be presented from each participating MH unit. These will include halothane results for vaporiser settings of 0.5% and 2.0%. The tissue bath concentration is usually lower than the required concentration, but halothane concentrations can also be found to be higher. Halothane concentrations can also vary within each lab. Caffeine analysis results collected over the past 24 months will also be presented from each participating lab. mild muscle soreness for 2 days. On the 3 rd day, pain increased, accompanied by severe muscle cramps in both upper legs. Symptoms were worsened by cold temperature. Due to pain, muscle weakness and swelling in both upper legs, he had sought medical attention on day 5 in a surgical outpatient clinic, where an ultrasound examination showed a "homogenous increase in muscle density of both quadriceps muscles". No laboratory tests except d-dimer were performed and after exclusion of an acute thromboembolic event, the patient was dismissed. Due to ongoing pain, he contacted our MH-Hotline 7 days after the exercise. He still felt sick and reported darker urine during the past 3 days. Body temperature was not yet measured. His general practitioner had already taken a blood examination one hour before the telephone call. One day later, laboratory analysis was available and showed a CPK of 39,628 U/l and myoglobin of 2,863 ng/ml, consistent with rhabdomyolysis. Also liver enzymes were elevated, but kidney function and potassium were normal. The patient reported a body temperature of 37.5°C in the morning. Due to the high CPK levels 7 days after exercise (normally, peak levels are expected within 48 to 96 h), we recommended an immediate admission to our unit and decided to start with dantrolene 2.5 mg/kg IV. After the initial dose of dantrolene he was admitted to an intermediate care unit for the first 24h. Case report: The patient, a 19 year old healthy male, who suffered childhood asthma, was anaesthetised for a planned mandible sagittal split and bimaxillar osteotomia due to prognathia. Anaesthesia was induced with propofol 140mg and suxamethonium 100mg was administered for muscle relaxation. Relaxation was not optimal but intubation was performed without problems. Anaesthesia was maintained with remifentanil (0.6-2.3µg/ kg/min) and desflurane (4.9-7vol%). After 15 minutes the airway pressure was 30mbar, which was initially interpreted as broncho-obstructivity due to his childhood asthma, however, it was probably a sign of muscle rigidity. The patient was given minute ventilation at 8.2 litres, with pCO 2 subsequently remaining stable for 2 hours. However, this increased to 10kPa and the patient began to sweat. The patient's temperature rose from 35.5°C 15 minutes after the start of the procedure to 37.9°C after 2.5 hours, but 15 minutes later the patient's temperature was 38.9°C. MH was diagnosed and dantrolene 380mg administered. Minute ventilation was increased to 12 litres FiO 2 100%. Cooling was performed with cold intravenous Ringer Acetate and surface cooling with ice. After 25 minutes the temperature was 37.6°C. The patient remained on the ventilator for 11 hours after anaesthesia. There was mild recrudescence at approximately 6 hours, with blood pH gradually falling from 7.43 to 7.31, and pCO2 increasing from 4.9 to 6.8. A 200mg dantrolene infusion was therefore administered over 2 hours, prior to extubation of the patient, such that the total dose of dantrolene administered was 580mg (29 vials). When the patient came round he reported severe muscle pain. With regard to surgery, the mandible sagittal split was performed, but the maxillary surgery was cancelled, leaving the patient unable to close his mouth or bite. Over the following 2 weeks, prior to the second surgery, the patient was only able to drink and lost 6kg. Second surgery was performed in trigger free anaesthesia without problems. In vitro contracture test revealed MH susceptible results (halothane contracture 2.8g and caffeine 1.3g). The patient has p. 552 Arg>Trp mutation in RYR1.
Conclusions: This report describes the time course for the onset of clinical features of MH, and associated changes in laboratory parameters, and during relapse. It clearly demonstrates the need for, and efficacy of, dantrolene, when used immediately. Since the introduction of intravenous dantrolene, mortality from MH has fallen from 80% to less than 5%. The European Guidelines for the management of a MH crisis recommend the immediate use of dantrolene sodium in combination with other symptomatic treatments as soon as a MH crisis is suspected, and recognise that an adult patient requires up to 50 vials for effective treatment. Background: The case reported involved the constellation of the above signs and exceptional circumstances meant that the right drug was not available at the time. Calcium channel blockers were given for life-saving reasons. However their value for that purpose is questionable and may be dangerous. Case report: Caucasian healthy man, 19 years old, was anesthetised with propofol bolus, remifentanil perfusion and sevoflurane maintenance. No muscle relaxants were used. Tachycardia was treated at 30 minutes with propranolol EV. Hypercapnia was evident at 50 minutes. Hyperthermia was confirmed at 60 minutes and specific attitudes were taken: sevoflurane was stopped and replaced by propofol perfusion, O 2 at 18 L/min, the patient was cooled, diuresis promoted and dantrolene was requested. At 70 minutes, muscle stiffness with ventilatory difficulties (P aw >40 cmH 2 O, CO 2ET >65 mmHg, SpO 2 =82%), axillar temperature=40.5 ºC (0,2 o C/min) -verapamil 5mg EV was given.
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The arterial blood gases: pH=7.23, K + =6.2mEq/L. Insulin and dextrose was used.
The dantrolene was delivered at 80min but the clinical improvement delayed their administration to 120min: 40 mg guided by K + blood analysis. At 48h the patient had severe legs oedema and at 72h blood CK = 12,700 U/L. He was discharged at one week and had fully recovered from renal and pereoneal nerve dysfunctions in the following months. This patient was treated in the maxillofacial department, which is away from the main hospital unit. The dantrolene unavailability is an issue of the anaesthesiologist's responsibilities. We did not carry out that specific checklist and were not aware of that situation. Portugal does not have laboratories for definitive diagnosis of malignant hyperthermia (MH) but the Larach clinical grading scale to predict patients susceptibility give 70 points; in the range of 50 points or more classified as almost certain. However, discussion of clinical signs and its sequential identification might question the therapeutic timing. If the therapy was implemented by the hypercapnia diagnosis, might the clinical evolution be different? And would the drug arrive in time for a life-saving situation? Is there any clinical indication for rechecking the local pharmacy?
We do not exclude the possibility that clinical improvement might have been a consequence of previous therapeutic measures; however, there was a temporal drug-effect. Background: Use of extracorporal circulation (cardiopulmonary bypass) during cardiac surgery can cause a systemic inflammatory response. This so called "post-perfusion-syndrome" (PPS) occurs in about a quarter of patients and results in clinical signs and symptoms of "systemic inflammatory response syndrome" (SIRS) in 2-10% of patients. This condition is clinically associated with mild hyperthermia, acidosis, tachycardia and vasoplegia. It is generally treated with cristalloid infusions and vasopressors, and is mostly subsided by the next morning, at the latest after 48h. Malignant hyperthermia is associated with a severe combined (respiratory and metabolic) acidosis, hyperlactatemia, hypercapnia, hyperthermia, grossly elevated serum levels of creatine kinase (CK) and acute renal failure.
Case report: We present a 23-year old patient, who gradually developed multi-organ failure following mitral valve repair for severe secondary mitral regurgitation due to dilated cardiomyopathy. His past medical history included partial hepatectomy for hepatoblastoma in childhood (1982) and partial lung resection due to recurrent pneumothoraces in 2002. Induction of general anesthesia was carried out with thiopentone, sufentanil and cisatracurium and was maintained with isoflurane as the hypnotic agent. Following surgery, the patient showed increased infusion requirements and was highly vasopressor-dependent. Due to oliguric renal failure and refractory metabolic acidosis, continuous veno-venous hemodiafiltration was instituted early. Increased volume and vasopressor needs gradually decreased within the first 30 hours. In conjunction with two episodes of body temperature peaks of > 39°C in "non-CRRT-intervals", the deferred but disproportionate elevation of serum-creatinkinase activity led to the clinical suspicion of malignant hyperthermia (Table 1) . Much later, long after hospital discharge, MH was confirmed by in vitro testing. Conclusions: High volume requirements and vasopressor-dependency occur commonly following surgical mitral valve repair, especially in patients with severely impaired left ventricular function. Differential diagnosis of hyperthermia on the ICU includes microbial triggers of the systemic inflammatory process, which could have been the case in this patient, where an infection might have been suspected. PPS and SIRS do not prompt any suspicion of malignant hyperthermia. Nevertheless, rare causes of both, hyperthermia and volume-depletion should be taken into account, even if the clinical course is rather mild in a way so that MH appears almost unlikely.
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Malignant hyperthermia on ICUsudden attack of the "snake"
Stephan Johannsen * , Susanne Mögele, Norbert Roewer, Frank Schuster Department of Anesthesia and Critical Care, University of Wuerzburg, Wuerzburg, 97080, Germany BMC Anesthesiology 2014, 14(Suppl 1):A11
Background: Fulminant malignant hyperthermia (MH) is a rare emergency that should be known to every medical professional although practical exposure is a rarity even for experienced anesthesiologists. The vast majority of documented MH cases occurred during general anesthesia in the operating room following application of volatile anesthetics and/or depolarizing muscle relaxants. With increasing utilization of the anesthetic conserving device AnaConDa® for sedation of intensive care patients, who could benefit from reduced duration of mechanical ventilation and earlier hospital discharge, volatile anesthetics made their way into the intensive care unit (ICU). Case report: With oral and written consent of the patient, we report the case of a 59-years old male, who was hospitalized due to persistent lumbalgia. On the second day of his hospital stay, increasing dyspnoe led to ICU admission and required tracheal intubation and mechanical ventilation. Sedation was maintained by propofol and sufentanil. A chest radiograph revealed bilateral pulmonary infiltration, suggestive of influenza pneumonia. Moxifloxacin, piperacillin/tazobactam and oseltamivir were started immediately. When after four days of mechanical ventilation an additional sedative became necessary, the anesthetic conserving device for sevoflurane sedation was installed. Suddenly, following five hours of sevoflurane administration, hemodynamic instability characterized by rapidly dropping arterial blood pressure occurred. Arterial blood gas analysis revealed severe acidosis (pH 7,17; pCO 2 70,4 mmHG; pO 2 104 mmHG (fiO 2 50%), base excess 9,8; lactate 0,6 mmol/l). A rapid increase of body temperature from 39.6°C to 40.7°C within 30 min was noticed. Creatine kinase and myoglobin levels were significantly elevated to maximum levels of 3455 U/L and 4197 µg/L due to acute rhabdomyolysis. As soon as MH was suspected, sevoflurane application was discontinued and Dantrolene was administered intravenously. After treatment the hemodynamic and metabolic situation gradually improved. The subsequent ICU stay remained uneventful and the patient was extubated on day 17 without neurological deficits. Nine month after the suspected MH event, the patient underwent muscle biopsy and in-vitro-contracturetesting at the Wuerzburg MH unit. His MH susceptibility was confirmed by significant contractures at the defined thresholds after halothane and caffeine exposure.
Conclusions: The presented case underlines the significance of MH as differential diagnosis in intensive care patients with hemodynamic and metabolic breakdown, if volatile anesthetics are used for sedation. Hence, awareness of the symptoms of MH and immediate initiation of adequate treatment can be crucial not only in the operating room. Note: This abstract was awarded by the EMHG as best clinical presentation.
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Update of the EMHG database on genetic variants in type 1 ryanodine receptor and their possible impact on phenotype Florian Grütter 1* , . Less invasive diagnosis using molecular genetic methods is of increasing importance, but knowledge about genetic variants in RYR1 is limited. The European MH Group (EMHG) RYR1 mutation database is not up-to-date and lacks information on a significant number of more recently identified variants or further knowledge on variants already in the database. Therefore, the need for an update in order to expand the use of molecular genetic testing is required.
The aim of this study was to collect information about variants in the RYR1 gene and their functional effect. Finally this information will be imported into the EMHG RYR1 mutation database. Materials and methods: PubMed was used for data collection. For the search, the three keywords "Malignant Hyperthermia", "Mutation" and "Ryanodine Receptor Calcium Release Channel" were used; the operator was "AND". Publication dates from the beginning of 2006 to the end of 2012 were selected. However, some older and newer studies were also included if they seemed important for the gain of information. Additionally, the considered papers had to be relevant for the human species. BMC Anesthesiology 2014, Volume 14 Suppl 1 http://www.biomedcentral.com/bmcanesthesiology/supplements/14/S1
Material and methods: We used Next-Generation Sequencing to look for coding sequence non-synonymous variants of RYR1 and CACNA1S. We applied two different target enrichment methods, Long-Range PCR and HaloPlex (Agilent), to be able to focus on particular regions of the genome.
Results: In our study we included a group of 80 unrelated MHS individuals who were previously screened for diagnostic mutations in RYR1 and were found negative. Another group consisted of discordant individuals, whose in vitro contracture test (IVCT) phenotype was at odds with their genotype for a familial diagnostic RYR1 mutation. The third studied cohort (n=38) were Exertional Heat Stroke patients, IVCT tested susceptible or normal.
Conclusions: Our results illustrate that Next Generation Sequencing provides broad genetic information quicker and at lower cost than conventional approaches. To improve understanding of malignant hyperthermia genetics, screening of susceptible individuals only for a limited number of diagnostic RYR1 variants is not sufficient. Studying the full length of RYR1 and CACNA1S coding sequence may also resolve some phenotype/genotype discordant cases. Finally, Next Generation Sequencing techniques provide opportunities for studying larger gDNA fragments or the whole genome, which may result in discovering some other genes linked to MH.
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The introduction of a targeted next generation sequencing diagnostic service for MH Dorota Fiszer 1* , Sarah Hobson 1 , Nickla Fisher 2 , Marie-Anne Shaw Following adoption of the dossier by the UGTN and validation of the sequencing strategy in a diagnostic facility, we are now in a position to offer testing. Testing will be offered to families where MH has been confirmed by IVCT and to new index cases. The cost of the sequencing is £530, compared to £3,500 for the IVCT. For index cases, the referring physician will be advised of the pre-test probability for their patient having MH as they may consider IVCT to be more cost-effective when the pre-test probability is low. Diagnostic reports will be issued in accordance with the joint guideline of the UK Association of Clinical Genetic Science (ACGS) and the Dutch Society of Clinical Genetic Laboratory Specialists (VKGL). Variants will be classified using a 5 class system: Reports for classes 1 -3 will advise IVCT. Variants will be assigned to a class depending on their reported frequency in databases (dbSNP, 1000 Genomes, EVS), segregation analysis and functional analysis.
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Targeted exon capture and NGS to investigate an undefined myopathy reveal RYR1 Background: The family under investigation consists of parents and two daughters, one being the proband. The mother and the proband have elongated facial features. The father and second daughter appear normal. The older daughter presented for elective tonsillectomy aged 8 years. She had severe masseter spasm after suxamethonium. The rest of the procedure was carried out under total intravenous anaesthesia. No blood gas analysis could be done, but a creatine kinase next day was significantly elevated (2934). This led to study of both parents. There was no family history of malignant hyperthermia but an undefined myopathy was suspected in mother and daughter. Both mother and father were diagnosed malignant hyperthermia (MH) susceptible by in vitro contracture test (IVCT). This prompted a DNA analysis for variants associated with MH. Materials and methods: Standard histochemistry, biochemistry and electron microscopy were carried out on muscle tissue from the mother. DNA from all four family members was analysed by targeted exon capture and next generation sequencing using the Ion Torrent platform. Blymphoblastoid cells were generated from all family members and assayed for abnormal calcium release. Results: The mother and both daughters carry a premature stop codon in ryanodine receptor subtype 1 (RYR1) as well an uncharacterized RYR1 variant inherited from the father. The mother also carries a second uncharacterized RYR1 variant, not inherited by either daughter. Muscle histology showed two cox-negative fibres suggestive of a mitochondrial disorder but not definitive. Calcium release assays using B-lymphoblastoid cells suggest a hypersensitive RyR1 channel in all four family members. Conclusions: The RYR1 variants identified cannot be definitively associated with susceptibility to MH, although the functional assays in B-lymphoblastoid cells suggest a hypersensitive channel. It is possible that the undefined myopathy is associated with another gene and the MH susceptible result by IVCT is unrelated to this condition. Further analysis of the family is required for a definitive diagnosis. Background: Many current methods for the detection of gene variants relevant for inherited disorders like malignant hyperthermia (MH) rely on the polymerase chain reaction (PCR). A positive PCR result for the genetic region of interest is required for downstream analysis like sequencing, restriction digestion or probe hybridization. However, it is sometimes overlooked that in order to obtain a true genotype, both paternal and maternal alleles must be represented in the PCR product. We present the The recurrency rates of mutations were low: of the 140 different variants observed, only 17 occurred more than once and only seven more than twice covering just 59 patients. Conclusions: Our longitudinal study reflects the known allelic heterogeneity of RYR1 mutations which poses a challenge for effective variant identification strategies to the present day. Although labor and cost have decreased with the advent of novel technologies, the problem of variant interpretation has increased proportional to the range and sensitivity of the screening methods. Since the vast majority of RYR1 variants result in amino acid substitutions their functional impact is not immediately evident. The causality criteria set by the EMHG are very strict in order to maximize clinical safety but this is in contrast to current practice in most other genetically heterogeneous disorders. In fact, the majority of "unclassified" variants identified in this study have been published in association with MHS and/or congenital myopathies and many of them meet all but one of the EMHG criteria. The reliability of computer algorithms for predicting the impact of amino acid substitutions on protein function has greatly improved but is still limited for large proteins like RyR1. It is fair to say that the initial hope of genetic analysis eventually replacing the invasive IVCT has proven vain for the majority of cases Background: This study aims to investigate gene expression in skeletal muscle in relation to age and MH status, focussing on particular genes of interest. Expression patterns have been analysed to address the question of whether major causative malignant hyperthermia (MH) mutations influence skeletal muscle ageing. In this context we have examined gene expression in MH susceptible, both with (MHS+) and without mutation (MHS-), and MH normal (MHN) material from in vitro contracture test (IVCT) muscle biopsies. Material and methods and results: Affymetrix data, derived from Affymetrix HG_U133Plus2.0 arrays on a cohort of 59 patient muscle cDNA samples, were analysed for potential genes of interest. These 59 samples comprised an age range of 10-71 years and included 27 MHS+, 13 MHS-and 19 MHN. Linear models (LM) were applied using R studio 3.0.1©. LM1 incorporated three independent variables: age, sex and malignant hyperthermia (MH) status and one dependent variable, expression. LM2 included just the sex and MH status variables, LM3 included only the age and MH status and LM 4 included all 3 variables but left out the age-MH status interaction term. Model comparison was completed using Akaike Information Criterion to establish the model that best fitted the observed data. The results were interpreted to ascertain those genes that may be of interest in the context of age, MH status and interaction between these two variables.
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The genes selected through this process, along with additional genes of interest based on criteria, such as involvement in store-operated calcium entry (SOCE) in skeletal muscle, were then subjected to TaqMan Gene Expression Analysis on a cohort of 108 cDNA samples (independent of the Affymetrix cohort) derived from patient muscle biopsies. This group comprised individuals with ages ranging from 10-87 years and represented individuals susceptible to MH, including those with a known mutation in RYR1 (42) and those with no mutation in RYR1 (22), and those with a normal phenotype (44). The results were analysed in a similar manner to the Affymetrix data, establishing any differences in gene expression according to the three dependent variables; age, sex and MH status.
Conclusions:
These results indicate a number of genes that may be of interest in relation to skeletal muscle ageing and MH status. Background: Malignant Hyperthermia (MH), central core disease (CCD), exertional heat stroke (EHS) and late-onset axial myopathy have been attributed to mutations in ryanodine receptor type 1 (RYR1). The RyR1 protein is over 5000 amino acid residues long, making manipulation of the mammalian gene difficult. The ryanodine receptor in Caenorhabditis elegans is UNC-68, which has 40% amino acid identity to the human protein.
Material and methods and results: Due to the compact nature of the C. elegans genome, the unc-68 gene is only 27 kb and is entirely contained in the fosmid clone WRM069cA02. Using recombineering, single base pairs were changed in this fosmid to establish nine different variants:
Using these altered fosmids, transgenic strains were developed by microinjection.
In order to establish these strains as a suitable model for studying RYR1 variants phenotyping assays were completed to assess the effects of halothane and caffeine on each of the strains developed. The rationale for this approach is based on the in vitro contracture test (IVCT). Both halothane and caffeine assays were carried out in S-medium. 1mM, 1.5mM, 2.0mM, 2.5mM concentrations of halothane were used, with halothane dissolved in DMSO prior to dilution in a liquid medium. The lowest concentration used is the lowest dose of halothane that will fully anaesthetise the worms and the highest dose is the maximum dosage from which worms can recover. Worms were immersed for 60 seconds and then body bends counted. 5mM, 10mM, 20mM, 40mM and 80mM concentrations of caffeine were used. Worms were immersed for 5 minutes and then body bends counted. This provided a measure of the effect of these chemicals on locomotion. Conclusions: Additional work will focus on examining the effect of age on the muscle of these transgenic strains. I will present the methods used to generate transgenic worms for each variant expressing gfp-myosin. This process involves mating strains to produce unc-68 worms expressing gfp, UV mutagenesis of this strain and then subsequent mating of the resultant strain with each of the muscle myopathy variant strains to introduce the gfp-myosin tag. This will enable visual examination of the muscle at different stages of the worm's lifespan. I will demonstrate the way in which ageing will be assessed and how it will be possible to interpret the age related changes that occur in the muscle and analyse this information for any potential effect of the variant on the ageing process. Background: Statins are currently the preferred agent for the treatment of hypercholesterolemia. However, myalgia, increased serum levels of creatinekinase (CK) and even rhabdomyolysis may occur, characterizing the cholesterol -lowering agents myopathy (CLAM), with a multifactorial aetiology. In statin monotherapy, the incidence of CLAM is 0.1 to 0.5 % and is dose related. RYR1 (ryanodine 1) gene alteration was observed in the patients with CLAM, an animal model of MH (malignant hyperthermia) showed hyper metabolism after simvastatin, simvastatin induced in vitro contractures in muscle of animal model and susceptibility to MH by IVCT (in vitro contracture test) was diagnosed in patients with CLAM. On the other way, postoperative rhabdomyolysis occurred in patients treated with cholesterol-lowering drugs, leading to the suggestion of suspend these medications prior to surgery or do not use succinylcholine in patients taking these drugs . But this stance is challenged by other groups. Thus, this study examined, in rats chronically exposed to simvastatin dose previously associated with muscle alteration, the outcome of the IVCT. Materials and methods: With approval of the local ethics committee, 30 male Wistar rats of 8 weeks of age were divided into 3 groups: A -control, B -Statin 5 mg/kg/day; C -Statin 20 mg/kg/day. For two months , via intragastric intubations using stainless curved feeding needle, the animals in groups B and C received simvastatin daily, diluted with carboxymethyl cellulose (CMC) 0.5 %, group A received only CMC. Next, the animals were anesthetized for removal of the vastus lateralis muscles, used in the IVCT according to the protocol of EMHG. The curves for each test were analysed to determine if there were contractures. Results: Two animals in the control group (0.3 +0.14 g), two animals in the 5mg statin group (0.2 ±0 g) and three animals in the 20 mg statin group (0.22 ±0.02) had greater than or equal to 0.2 g contracture in the presence of 2% halothane. One animal in the 5mg statin group (0.28 g) and two group of the 20 mg statin group (0.26 +0.02 g) had greater than or equal to 0.2 g contracture in the presence of 2mM caffeine. But these contractures were minimal and there was no statistical difference in the number of animals per group with this change (chi-square, p not significant).
A22

Conclusions:
A preliminary analysis of these findings suggests that doses of 5-20 mg/kg of simvastatin were not sufficient to cause contractures and do not increase the risk of MH crisis in healthy individuals in monotherapy.
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Accuracy MH is not a part of any national governmental or healthcare ministry program, so our work is not sponsored and is totally volunteered. Our small team is full of enthusiasm, but this can't cover expenses for lab equipment. We had received financial support from two commercial sponsors, but it was not too big and we were not able to buy all the necessary things. We had received a great support from our French colleagues who shared their experience, knowledge, soft-and hardware and even some important lab pieces. This report is intended to be a kind of «Call for help». If your lab has some equipment to share (old, not in use and even out of service) we would appreciate any contribution and support. (1991, 1993, 1995, and 1998) were formatted as a list of steps. In the first ten years, changes were mainly to content rather than design. For example, dantrolene administration was prioritized -
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Step 1 "GET HELP.GET DANTROLENE," changing the anesthesia circuit tubing and CO 2 absorbent were no longer recommended, and specific dosages were given for insulin and glucose for the treatment of hyperkalemia. Released in 2003, the fifth version of the MH poster had a completely different format with three separate sections for diagnosis (including masseter spasm and sudden cardiac arrest in a child), acute treatment, and post acute care. The sentences were converted to bullet points and formatted in columns to make reading easier. Bolded text was also used to highlight common errors, such as failing to use sterile water to dilute the dantrolene, and the avoidance of calcium channel blockers. The next two versions (2005 and 2008) retained this format with added information on myoglobinuria and the maintenance of adequate urine output. The latest version (2011), has a dramatically different look. The most notable changes are the use of color, pictures, and an algorithm style rather than bullet-point steps.
Over 20,000 posters have been distributed over past several decades. The use of the posters/algorithm has been incorporated into simulation-based scenarios involving MH; the posters have has been translated into different languages, and modified for inclusion in the Stanford Emergency Manual. Conclusions: The MHAUS MH treatment poster was one of the, if not the first cognitive aid to be used in anesthesia practice. It has evolved from a simple list of steps to a visually appealing and easy to follow algorithm that incorporates all key treatment elements and common diagnostic questions.
Although it is impossible to measure how the "poster" has influenced the recognition and treatment of MH, the fact that it is widely distributed and continues to be in demand attests to its probable effectiveness. Three meetings and many exchanges by mail between the experts and with the colleagues in charge of the Guidelines Board of the SFAR were necessary to obtain a consensus from all the participants. Eventually the text was published on the site of the SFAR in October 2013. http://www.sfar.org/ article/1080/recommandations-d-rsquo-experts-pour-le-risque-d-rsquohyperthermie-maligne-en-anesthesie-reanimation-sfar-crc-12-septembre-2013. Dr. Krivosic-Horber has been invited to present the Guidelines with a written paper in the annals, at the annual meeting of the SFAR in Paris in September 2014. Index of the Guidelines:
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1) Screening of the risk of MH susceptibility during the "consultation d'anesthesie" (which is legally mandatory in France).
2) How to do the diagnosis of MH susceptibility (IVCT or Genetic?) 1) How to perform an anesthesia free of MH risk.
2) Management of the MH crisis: presented as a poster with diagnosis and treatment on one side and stock and preparation of dantrolene on the other side.
3) What to do after the crisis. 4) The addresses of the MH centers and a map showing the type of diagnosis they can provide.
P O S T E R P R E S E N T A T I O N S P1
Malignant hyperthermia and beyond -a virtual BioBank Rosie Underwood 1,2* , Nickla Fisher 2 , Dorota Fiszer 1,2 , Philip Hopkins 1,2 , Marie-Anne Shaw Background: In order to address the complexities of Malignant Hyperthermia (MH) and genetically related disorders it is necessary to access and interrogate easily all information collected over the last 40 years, in addition to incorporating the continuous supply of new information. Material and methods: With all types of data held in a single database we are interested in a number of projects including:
• A more detailed analysis of in vitro contracture test (IVCT) data to better define phenotype for research purposes, and to assess the effects of specific mutations on the range of phenotypes. We have previously conducted an analysis of the effects of a number of ryanodine receptor type 1 (RYR1) mutations on IVCT and MH reaction phenotypes.
• We have previously published preliminary work considering the possibility of genetic modifiers, and this is a topical area with the role of common versus rare variants as contributors to complex disorders being hotly debated. It will be possible to initiate small projects on the effects of previously identified single nucleotide variants and SNV-SNV interactions on phenotype.
• To analyse observations such as discordancy in greater depth.
• To assess the statistical power for large-scale studies such as a Genome Wide Association Scan. Results: In Leeds, we have initiated a relational database, developed using FileMaker Pro®. This software was specifically chosen due to its versatility to set permissions and access rights ensuring that all data stored is kept secure. A private, restricted access file, currently holds nearly 10,000 records, with one individual being represented as one record. It contains names, family codes, date of birth and diagnostic identification numbers. This file preserves anonymity by assigning individuals within families a unique identification number, subsequently acting to link all other data. This private file is held on a different server from the second wider access 'public' file, whose data is linked to the private file only by the unique identifier. This 'public' file holds a range of information in the form of tables:
• The family table describes familial relationships, which will be suitable for exporting to .ped files, enabling this data to be imported directly into genetic analysis programs.
• The process table which holds sample collection and storage information, together with the procedures undertaken e.g. histology, exome sequencing, preparation of myoblasts.
• The phenotype and IVCT tables contain information such as clinical details and 'raw' IVCT data, allowing for a more detailed analysis in addition to the clinical definition of MHS versus MHN.
• The genotype table contains all genotypic information to date such as mutation testing results.
